Legal & General Group
NWBO

Legal & General Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Legal & General Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-9,752
Closed -$14K – 3003
2016
Q1 		$14K Hold
9,752
– – ﹤0.01% 2716
2015
Q4 		$31K Hold
9,752
– – ﹤0.01% 2636
2015
Q3 		$59K Hold
9,752
– – ﹤0.01% 2366
2015
Q2 		$93K Buy
+9,752
New +$85.4K ﹤0.01% 2166

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Legal & General Group's NWBO Position: Q2 2016 in Review

Legal & General Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 9,752 shares — an estimated $14K sold.

Legal & General Group first reported a position in NWBO in Q2 2015 and held it in 4 quarters. The position peaked at $93K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • Legal & General Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • Legal & General Group sold 9,752 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $14K.
  • Legal & General Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2015 and held it in 4 quarters.
  • Legal & General Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $93K in Q2 2015.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Legal & General Group's 13F filing for Q2 2016, filed 16 Aug 2016.